

DEC 14 2002
PATENT & TRADEMARK OFFICE

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	09/424,498
Filing Date	November 24, 1999
First Named Inventor	
Art Unit	1653
Examiner Name	H. Schnizer
Attorney Docket Number	20695D-001000US

RECEIVED

DEC 1 2002

TECH CENTER 1600/291

U.S. PATENT DOCUMENTS

Examiner	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
HS	AA	4,814,277		03-21-1989	Eibl et al.	
HS	AB	5,610,147		03-11-1997	Seelich	
HS	AC	5,639,730		06-17-1997	Eibl et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
HS	AD	CA	1239583	✓	07-26-1988	Immuno Aktiengesellschaft fur chemisch- medizinische Produkte		<input type="checkbox"/>
HS	AE	CA	2071567	✓	12-21-1992	Immuno Aktiengesellschaft		<input type="checkbox"/>
HS	AF	EP	0 131 740	B2 ✓	09-28-1994	New York Blood Center, Inc.		<input type="checkbox"/>

Examiner Signature	<i>H. Schnizer</i>	Date Considered	3-31-03
-----------------------	--------------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	09/424,498		
		Filing Date	November 24, 1999		
		First Named Inventor			
		Art Unit	1653		
		Examiner Name	H. Schnizer		
Sheet	2	of	2	Attorney Docket Number	20695D-001000US

RECEIVED

DEC 10 2002

TECH CENTER 1600/2900

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
JS	AG	BORCHIELLINI, ALESSANDRA, et al; Quantitative Analysis of von Willebrand Factor Propeptide Release In Vivo: Effect of Experimental Endotoxemia and Administration of L-Deamino-8-D-Arginine Vasopressin in Humans; <i>Blood</i> ; October 15, 1996; pp. 2951-2958; Volume 88, No. 8	✓
	AH	LENTING, PETER J., et al.; The Life Cycle of Coagulation Factor VIII in View of Its Structure and Function; <i>Blood</i> ; December 1, 1998; pp. 3983-3996; Volume 92, No. 11	✓
	AI	STEDMAN'S MEDICAL DICTIONARY; 26 th Edition; copyright 1995; p. 1300	✓
	AJ	TURECEK, PETER I., et al.; In vivo and in vitro processing of recombinant pro-von Willebrand factor; <i>Histochem Cell Biof</i> ; 2002; 123-129; Volume 117	✓
	AK	VÁRADI, KATALIN, et al.; Thrombin-mediated In Vitro Processing of Pro-von Willebrand Factor; <i>Thromb Haemost.</i> 2001; pp. 1449-1458; Volume 86	✓
JS	AL	WAGNER, DENISA D, et al.; Divergent fates of von Willebrand factor and its propolypeptide (von Willebrand antigen II) after secretion from endothelial cells; <i>Proc. Natl. Acad. Sci USA</i> ; April 1987; pp. 1955-1959; Volume 84	✓

Examiner Signature		Date Considered	3-31-03
-----------------------	--	--------------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

DE 7088808 v1